Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Heartcare Medical Technology Corp. Ltd. Class H ( (HK:6609) ) has issued an update.
Shanghai Heartcare Medical Technology Corp. Ltd. has announced a proposed issuance of 1,000,000 domestic shares under a specific mandate, priced at HK$45.00 each, as part of a subscription agreement with Mr. Zhang. This move aims to enhance the company’s competitiveness and secure additional funds for its operations. The issuance is subject to shareholder approval and regulatory conditions, and a special resolution will be proposed at upcoming meetings to authorize the board to manage the issuance process.
The most recent analyst rating on (HK:6609) stock is a Hold with a HK$47.00 price target. To see the full list of analyst forecasts on Shanghai Heartcare Medical Technology Corp. Ltd. Class H stock, see the HK:6609 Stock Forecast page.
More about Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai Heartcare Medical Technology Corp. Ltd. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on enhancing its competitiveness and raising funds to support its operating activities and stable business development.
Average Trading Volume: 66,761
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.77B
Find detailed analytics on 6609 stock on TipRanks’ Stock Analysis page.